Altum Pharmaceuticals
  • About
    • History
    • Board of Directors
    • Management
    • Advisors
  • Disease Areas & Unmet Need
    • COVID-19
    • Cervical Dysplasia/Cancer and Human Papilloma Virus (HPV)
    • Cancer Bone Metastases & Skeletal Related Events
  • Pipeline
    • Pipeline Overview
    • AP-001
    • AP-002
    • AP-003
    • BiPhasix™ Platform
  • News & Events
  • Contact
Select Page

Altum Signs Exclusive Worldwide License Agreement

by Altum Pharmaceuticals | Mar 27, 2017 | Altum Pharmaceuticals, BiPhasix, Business

Vancouver, British Columbia, March 27, 2017 – Altum Pharmaceuticals Inc. (“Altum” or the “Company”), a biopharmaceutical company engaged in clinical and commercial development of novel pharmaceutical compounds to treat cancer and autoimmune disorders, announces today...

Recent Posts

  • Altum Pharma Appoints New Executive Chair of the Board of Directors
  • Altum Pharmaceuticals, Inc. completes acquisition of Lexi Pharma Inc, and its pipeline of novel therapies for bone disease and oncology
  • Altum Signs Exclusive Worldwide License Agreement
  • Altum Pharmaceuticals Enters into Agreement with Ortac Capital & Ortac AG

Archives

  • October 2018
  • April 2018
  • March 2017
  • June 2016
  • Privacy
  • Terms of Use
  • Cookie Policy
  • English
  • German
© 2020 Altum Pharmaceuticals Inc. All rights reserved.
We use cookies, including 3rd party cookies (e.g. Google, LinkedIn) to improve your experience on our website, analyse our traffic. By continuing to use this website, you accept our cookie policy.AcceptCookie policy